|Predicting Sites of Metabolism with Artificial Neural Network Ensembles|
Marvin Waldman, Robert Fraczkiewicz, JinhuaZhang, Robert D. Clark and Walter S. Woltosz
Hepatic first-pass metabolism of many drugs and pro drugs plays a key role in their oral bioavailability. The human cytochrome P450 enzymes are responsible for the metabolism of most drugs. Knowledge of likely sites of metabolic attack in a drug molecule can aid in designing out unwanted metabolic liabilities early on in the drug discovery process, as well as in the design of pro drugs where metabolic transformation is desired.
|GALAS Modeling Methodology Applications In The Prediction Of Drug Metabolism Related Properties|
Remigijus Didziapetris, Justas Dapkunas, Andrius Sazonovas and Pranas Japertas
Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task and is performed only at the later phases of drug development. Therefore the possibility to predict possible sites of human liver microsomal (HLM) metabolism using in silico techniques would be a very attractive feature for any medicinal chemist.
|Effective Use of In-Silico Tools in Lead Optimization|
Pranas Japertas, Andrius Sazonovas and Kiril Lanevskij
Of all the challenges facing medicinal chemists in general, one of the most significant must be transforming an active molecule into a viable drug. Lead optimization efforts are guided by a combination of factors, such as potency, ease of synthesis, patentability concerns, specific synthetic constrains of the interaction with the target, as well as the lead’s toxicity and ADME properties.
Dr Brian Everatt1 C.Chem., FRSC, Simon Tullett2
Lab2Lab is a novel approach to submitting and transporting samples for analysis across an entire site. Sample tubes are registered and methods selected, an ELN reference is assigned and the sample tube is placed into the “Sender”. The system transports the samples using low pressure compressed air and directs them to the most appropriate analytical instrumentation available. The analytical results are then automatically returned to the originators ELN.
|QSAR Model of Regioselectivity of Metabolism in Human Liver Microsomes: Development, Validation, Comparison and Adaptation to Novel Compounds|
Justas Dapkunas, Andrius Sazonovas and Pranas Japertas
Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task which is performed only in late drug development phases. Therefore the ability to predict possible sites of human liver microsomal metabolism using in silico techniques would be highly beneficial for any medicinal chemist.
|Ensuring the Quality of Registered Compounds in a Drug Discovery Environment – A Multidisciplinary Approach|
Ryan Sasaki and Tara Sinclair
Lexicon Pharmaceuticals have demonstrated that a practical automated verification system using HPLC, LC/MS, and 1D and 2D NMR can be implemented in an industrial/pharmaceutical environment. This system has proven to be robust, and provides added value to compound collection integrity and quality.
| Synthesis and Biological Evaluation of Novel Quinol dimethyl ethers as Potential Anticancer and Antimicrobial Agents|
Ibrahim Chaaban, El Sayeda M. El Khawass, Mona A. Mahran, Heba A. Abd El Razik1, Nehad S. El Salamouni, Abeer E. Abdel Wahab
As a part of an ongoing research program devoted to the finding of new structural leads with potential chemotherapeutic activities, particular attention has been given to the pronounced anticancer activity of several quinol dimethyl ethers. Several analogs incorporating the above-mentioned quinol dimethyl ether counterpart together with a pyrazole moiety exhibited a potential antitumor activity.
|The use of the IV microtracer technique to drive formulation optimisation|
Vanessa Zann, Paul Dickinson, Wang Wang Lee, George Kirk, Owen Jones, Andy Gray, Davindera Singh Sanghera, Mark Seymour, Jo Collier, Lloyd Stevens, Julie Dent
Strategy: Use IV microtracer techniquer to de risk compounds with PK issues and drive formulation development
|Addressing the challenges of poor solubility: Rapid development and clinical evaluation of a lipid based formulation to enhance oral bioavailability of amuvatinib (MP-470)|
P.D. Scholes, J. McDermott, J. Vertommen, J-L Colin, G Choy, M Azab, R Joshi and S. Redkar
Physiochemical and biopharmaceutical properties of new chemical entities are presenting increasing challenges to successful oral drug delivery. Here we present data on amuvatinib, a novel multi-targeted tyrosine kinase inhibitor specifically designed to be a potent inhibitor of mutant c-Kit and PDGFRalpha.